Comparison of alternate day atorvastatin treatment to daily treatment in maintaining LDL-Cholesterol targets in patients with variable coronary risk profile
Journal of Cardiovascular Pharmacology,  Clinical Article

Pattanaika S et al. – Alternate–day treatment of atorvastatin was inferior to daily treatment in maintaining the INCEP–ATPII goal.

Methods
  • This randomized, open label trial included 300 patients of dyslipidemia or coronary artery disease on stable doses of atorvastatin.
  • These patients met their respective NCEP–ATPIII cholesterol goals and randomized to receive the same doses of atorvastatin every day (QD) or every–other–day (QOD) in 1:1 ratio for 12 weeks.
  • The efficacy criteria were (1)proportion of patients maintaining the LDL–C goal (2)comparison of changes in the TC, LDL–C, HDL–C and TG levels from baseline.

Results
  • Proportions of patients maintaining their LDL–C goals in QD and QOD groups at 6 weeks were 83.9%(60.3–97.5) Vs 70.9%(59.3–82.5) [p< 0.01] and at 12weeks were 84.6%(70.9–98.3) Vs 73.8%(63.8–83.8) [p< 0.05].
  • Per–protocol analysis showed 95.5%(80.0–111.0) Vs 79.1%(66.2–92.0)[p< 0.001] patients at 6 weeks and 91.9%(82.0–106.8) Vs 77.4%(64.8–90) [p< 0.05] patients at 12 weeks had maintained their LDL–C goals in QD and QOD groups.
  • Significant increase was observed in the levels of TC, LDL–C and TG at 6 and 12 weeks compared to baseline values in the QOD group.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close